InvestorsHub Logo
Followers 22
Posts 4084
Boards Moderated 0
Alias Born 04/29/2016

Re: None

Tuesday, 04/11/2017 1:34:09 PM

Tuesday, April 11, 2017 1:34:09 PM

Post# of 233152
This drug is NOT a mono drug...simply not potent enough...no side effects due to lack of potency, thus compromising efficacy and subsequent rebound. Looks like Adjunct may only bring in 25 to 50M per year...very little demand for HAART patients to fill that N=30 target...or, it is filled and the CC will cover the post hoc, subgroup,essay and dosing restructuring. Adding a BOD member at this time (Knee surgeon) means NO BO in sight, Also, trading volume is anemic...no anticipation or interest. JMHO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News